Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $21.9B | $20B | $18.6B | $4.6B | $4.7B | |
| Gross Profit | $1.2B | $720M | -$800M | -$66M | -$30M | |
| Operating Income | $580M | $111M | -$1.4B | -$205M | -$185M | |
| EBITDA | $1.6B | $1B | -$206M | $30M | $103M | |
| Diluted EPS | $0.67 | -$0.96 | -$3.40 | -$0.52 | -$0.51 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.1B | $8.3B | $6.9B | $6B | $6.7B | |
| Total Assets | $18.1B | $19.7B | $18.1B | $16.8B | $20.3B | |
| Current Liabilities | $3.3B | $3.6B | $3.3B | $3.3B | $3.3B | |
| Total Liabilities | $13.8B | $12.4B | $9.8B | $9.7B | $14.6B | |
| Total Equity | $4.3B | $7.3B | $8.3B | $7.1B | $5.7B | |
| Total Debt | $5.4B | $4.5B | $3.5B | $3.8B | $8B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.1B | $1.2B | -$921M | -$84M | -$143M | |
| Cash From Investing | -$679M | -$598M | -$3.1B | -$146M | -$138M | |
| Cash From Financing | -$1.5B | -$589M | $4.1B | $159M | $286M | |
| Free Cash Flow | $1.4B | $540M | -$1.5B | -$235M | -$300M | |
Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.
In the current month, CLF has received 4 Buy ratings 7 Hold ratings, and 0 Sell ratings. The CLF average analyst price target in the past 3 months is $12.81.
According to analysts, the consensus estimate is that Cleveland-Cliffs, Inc. share price will drop to $12.81 per share over the next 12 months.
Analysts are divided on their view about Cleveland-Cliffs, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cleveland-Cliffs, Inc. is a Sell and believe this share price will rise from its current level to $7.60.
The price target for Cleveland-Cliffs, Inc. over the next 1-year time period is forecast to be $12.81 according to 11 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Cleveland-Cliffs, Inc. is a Hold. 7 of 11 analysts rate the stock a Hold at this time.
You can purchase shares of Cleveland-Cliffs, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cleveland-Cliffs, Inc. shares.
Cleveland-Cliffs, Inc. was last trading at $13.76 per share. This represents the most recent stock quote for Cleveland-Cliffs, Inc.. Yesterday, Cleveland-Cliffs, Inc. closed at $13.75 per share.
In order to purchase Cleveland-Cliffs, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.